Question 1

What is Denovo Biopharma's core technology?

Accepted Answer

Denovo Biopharma's core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late-stage drugs that have completed clinical trials with unsatisfactory efficacy, as it enables the identification of biomarkers correlated to patients' responsiveness to drug candidates.

Question 2

What therapeutic areas does Denovo Biopharma focus on?

Accepted Answer

Denovo Biopharma's technology platform can be broadly applied to biomarker discovery and biomarker-guided drug development in many therapeutic areas, including oncology, neurology, metabolic, cardiology, and immunology.

Question 3

How does Denovo Biopharma's technology enable new clinical trials for late-stage drug candidates?

Accepted Answer

Denovo Biopharma's technology enables the identification of biomarkers correlated to patients' responsiveness to drug candidates retrospectively. By using this approach, the company can design new clinical trials targeting a specific patient population more likely to respond to the drug, which can lead to significant improvements in efficacy and/or reduced adverse effects.

Denovo Biopharma

Company Overview

Company Name

Address

Website

About Denovo Biopharma

Similar Companies

Frequently Asked Questions about Denovo Biopharma

What is Denovo Biopharma's core technology?

What therapeutic areas does Denovo Biopharma focus on?

How does Denovo Biopharma's technology enable new clinical trials for late-stage drug candidates?

Social Profiles

Key Decision Makers